Drug Security Forum

Drug Provision for Cancer Patients

14 Jun , 10:00–11:30
‘Ensuring Drug Security’ Russian Pharmaceutical Forum
Pavilion G, conference hall G6

Government programmes for inpatient and outpatient drug provision for cancer patients enable full-scale care to be provided to patients. However, their availability and quality may vary from region to region. As oncology enters the era of personalization, the volume of molecular genetic tests is steadily increasing. According to oncology experts, the volume of molecular genetic, pathological, and anatomical studies is unevenly distributed at regional level each year. As far back as last year, it had been proposed to update financing and the number of personalized diagnostics, taking into account morbidity, volume standards, and financial resources for pathological and molecular-genetic studies in view of analysis of execution in 2022 and define the minimum acceptable list of such studies taking into account clinical guidelines. This experience must be analyzed. Combination chemotherapy is gaining in relevance and use, which requires revision of clinical guidelines, additional clinical trials, and revision of clinical statistical groups. Is the level of supply of the required volume of drugs to cancer centres sufficient today? Are there interchangeability schemes for biosimilars and generic oncology drugs within treatment standards? To what extent are domestic manufacturers prepared to take on the necessary volume of supply?

Evelina Zakamskaya, Chief Editor, Doctor TV Channel

Irina Borovova, President, Association of Cancer Patients "Zdravstvuy!"
Yan Vlasov, Co-Chairman, Russian Patient Association
Evgeny Kamkin, Deputy Minister of Health of the Russian Federation (online)
Andrey Kaprin, General Director, Federal State Budgetary Institution National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation; Сhief Freelance Specialist Oncologist of the Ministry of Health of the Russian Federation (online)
Diana Kobesova, Deputy General Director for Pharmaceutical Business Development, Rusatom Healthcare
Galina Shemanaeva, Acting Deputy Head of Administration of the Tambov Region